文献速递食管胃疾病与幽门螺杆菌

新型钾离子竞争性酸阻滞剂DWP14012在健康男性受试者中的安全性、耐受性、药效学与药代动力学

Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects.
PubMed 文献 · Aliment Pharmacol Ther · 2018-06-04

在无幽门螺杆菌感染的健康男性中开展随机、双盲、双模拟、安慰剂和阳性药对照的单次和多次递增剂量研究。DWP14012总体耐受性良好,多次给药后肝毒性不高于安慰剂,可快速持续抑制胃酸分泌24小时,呈明确剂量和暴露-效应关系。

要点

  • DWP14012单次10-320 mg、多次20-160 mg每日一次均总体耐受良好。
  • 多次给药后DWP14012肝毒性不高于安慰剂。
  • 给药后24小时胃酸抑制快速且持续,呈剂量和暴露-效应关系。

核心结论

  • DWP14012在健康受试者中耐受性良好,并显示出快速且持久的胃酸抑制效果。
  • 这些结果支持在酸相关疾病患者中进一步研究DWP14012。

研究设计与样本

  • 随机、双盲、双模拟、安慰剂和阳性药对照的单次和多次递增剂量研究,在无幽门螺杆菌感染的健康男性受试者中开展。
  • 单次递增剂量研究纳入72例,随机接受单次口服DWP14012 10-320 mg、埃索美拉唑或安慰剂。
  • 多次递增剂量研究纳入48例,按8:2:2随机接受每日一次DWP14012 20-160 mg、埃索美拉唑或安慰剂,连续7天。
  • 耐受性采用microRNA-122检测评估,药效学通过24小时胃内pH监测评估,药代动力学评估血浆和尿液DWP14012浓度。

主要发现

  • DWP14012总体耐受性良好。
  • 多次口服给药后,DWP14012的肝毒性不高于安慰剂。
  • DWP14012在给药后24小时内快速且持续抑制胃酸分泌。
  • 观察到明确的剂量-反应和暴露-反应关系。
  • 多次递增剂量研究中DWP14012血浆浓度呈剂量比例增加,而单次递增剂量研究中DWP14012在血浆中未见显著蓄积。

临床怎么用

  • 原文结论指出这些结果支持在酸相关疾病患者中进一步研究DWP14012。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A novel potassium-competitive acid blocker, DWP14012, is in clinical development as a potential alternative to proton pump inhibitors for the treatment of acid-related diseases. AIMS: To evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012 in humans. METHODS: A randomised, double-blind, double-dummy, placebo- and active-controlled, single- and multiple-ascending dose (SAD and MAD, respectively) study was conducted in healthy male subjects without Helicobacter pylori infection. Subjects randomly received a single oral dose of 10-320 mg DWP14012, esomeprazole (active comparator) or placebo in the SAD study (n = 72) and once daily doses of 20-160 mg DWP14012, esomeprazole or placebo for 7 days in the MAD study (n = 48; 8:2:2). Tolerability was evaluated using a microRNA-122 assay. Pharmacodynamics were evaluated through 24-hour gastric pH monitoring, and pharmacokinetics were evaluated plasma and urine DWP14012 concentrations. RESULTS: DWP14012 was generally well tolerated. The liver toxicity of DWP14012 was not higher than that of placebo after multiple oral administrations. DWP14012 showed rapid and sustained suppression of gastric acid secretion for 24 hours after dosing. Clear dose-response and exposure-response relationships were observed. Plasma concentrations of DWP14012 increased in a dose-proportional manner in the MAD study, whereas in the SAD study, DWP14012 did not significantly accumulate in the plasma. CONCLUSIONS: DWP14012 was well tolerated, and showed a rapid and long-lasting gastric acid suppression effect in healthy subjects. These results justify further investigation of DWP14012 in patients with acid-related disorders.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sunwoo J, Oh J, Moon SJ, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018. PMID: 29863280. doi:10.1111/apt.14818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。